Stellungnahme der DGVS und der DGHO zur frühen Nutzenbewertung von Trifluridin/Tipiracil zur Therapie des Magenkarzinoms bei vorbehandelten Patienten

• Literatur

• 1 Krebs in Deutschland 2015/2016. 2019 Verfügbar über: 12. Auflage. http://www.gekid.de
• 2 Lordick F. et al. Magenkarzinom. Leitlinien von DGHO, OeGHO, SGMO und SGH+SSH, Status Dezember 2018. https://www.dgho-onkopedia.de/de/onkopedia/leitlinien/lungenkarzinom-nicht-kleinzellig-nsclc
• 3 Interdisziplinäre S3-Leitlinie: Magenkarzinom – Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs. Registernummer 032–009OL, August 2019. https://www.awmf.org/uploads/tx_szleitlinien/032-009l_S3_Magenkarzinom_Diagnostik_Therapie_Adenokarzinome_oesophagogastraler_Uebergang_2019-12.pdf
• 4 Shitara K, Doi T, Dvorkin M. et al. Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebocontrolled, phase 3 trial. Lancet Oncol 2018; 19: 1437-1448
• 5 Kang YK, Boku N, Satoh T. et al. Nivolumab in patients with advanced gastric or gastrooesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2017; 390: 2461-2471
• 6 Chen LT, Satoh T, Ryu MH. et al. A Phase 3 Study of Nivolumab in Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer (ATTRACTION-2): 2-year Update Data. Gastric Cancer 2019;
• 7 Fuchs CS, Doi T, Jang RW. et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial. JAMA Oncol 2018; 4: e180013
• 8 Cherny NI, Sullivan R, Dafni U. et al A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol 2015; 26: 1547-1573 . doi:10.1093/annonc/mdv249
• 9 Cherny NI, Dafni U, Bogaerts J. et al ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol 2017; 28: 2340-2366 . doi:10.1093/annonc/mdx310
• 10 Smyth EC, Moehler M. Late-line treatment in metastatic gastric cancer: today and tomorrow. Ther Adv Med Oncol 2019; 11: 1758835919867522 . doi:10.1177/1758835919867522